Mega menu

Home
Product regulation
Product regulation

Understand your obligations and access industry Guidance and other information about the products we regulate.
Safety and shortages
Safety and shortages

Access information about product recalls, shortages and other alerts, and learn how we manage safety.
Resources and guidance
Resources and guidance

Get information to help you understand our work, regulations and industry obligations.
Business services
Business services

Access our systems to submit applications, manage forms, make payments and communicate securely.

Boehringer Ingelheim Pty Ltd

Regulatory activities for this sponsor.

- LinkedIn
- (Twitter)
- Facebook
- Email

Loading...

Type

ARTG (88)
Cancellation by sponsor (46)
Prescription medicine registration (11)
Australian public assessment report (AusPar) (7)
Designation or determination (2)
Prescription medicine decision summary (1)

Date

2026 (2)
2025 (4)
2024 (5)
2023 (9)
2022 (3)
2021 (6)
2020 (14)
2019 (2)
2018 (15)
2017 (4)
2016 (14)
2015 (13)
2014 (4)
2013 (14)
2012 (3)
2011 (8)
2010 (5)
2008 (4)
2007 (2)
2003 (1)
2002 (3)
2001 (4)
2000 (3)
1999 (7)
1998 (1)
1996 (1)
1993 (1)
1992 (1)
1991 (2)

Search

Sponsor content

155 result(s) found, displaying 11 to 20

AusPAR: Spevigo

18 July 2024

Australian public assessment report (AusPar)

Spevigo (spesolimab) has been approved for the treatment of generalised pustular psoriasis, a rare but severe form of psoriasis that involves flares of widespread, non-infectious, macroscopically visible pustules.
JARDIANCE (Boehringer Ingelheim Pty Ltd)

6 February 2024

Prescription medicine registration

Active ingredients: empagliflozin.
Spevigo

8 December 2023

Prescription medicine decision summary

Spevigo (spesolimab) is approved for the treatment of flares in adult patients with generalised pustular psoriasis.
SPEVIGO (Boehringer Ingelheim Pty Ltd)

5 September 2023

Prescription medicine registration

Active ingredients: spesolimab.
SRIVASSO RESPIMAT tiotropium 2.5 micrograms/actuation solution for inhalation cartridge Cancelled under Section 30(1)(c) of the Act

8 May 2023

Cancellation by sponsor

Requested by Boehringer Ingelheim Pty Ltd
ESOVYND RESPIMAT tiotropium 2.5 micrograms/actuation solution for inhalation cartridge Cancelled under Section 30(1)(c) of the Act

8 May 2023

Cancellation by sponsor

Requested by Boehringer Ingelheim Pty Ltd
YANIMO RESPIMAT 2.5 micrograms/2.5 micrograms tiotropium (as bromide monohydrate)/olodaterol (as hydrochloride) solution for inhalation cartridge Cancelled under Section 30(1)(c) of the Act

8 May 2023

Cancellation by sponsor

Requested by Boehringer Ingelheim Pty Ltd
SPIOLTO RESPIMAT 2.5 micrograms/2.5 micrograms tiotropium (as bromide monohydrate)/olodaterol (as hydrochloride) solution for inhalation cartridge Cancelled under Section 30(1)(c) of the Act

8 May 2023

Cancellation by sponsor

Requested by Boehringer Ingelheim Pty Ltd
STRIVERDI RESPIMAT olodaterol (as hydrochloride) 2.5 microgram/actuation solution for inhalation cartridge Cancelled under Section 30(1)(c) of the Act

8 May 2023

Cancellation by sponsor

Requested by Boehringer Ingelheim Pty Ltd
SPIRIVA RESPIMAT tiotropium 2.5 micrograms/actuation solution for inhalation cartridge Cancelled under Section 30(1)(c) of the Act

8 May 2023

Cancellation by sponsor

Requested by Boehringer Ingelheim Pty Ltd

Pages

First page
Previous page
Page 1
Current page 2
Page 3
Page 4
Page 5
Page 6
Page 7
Page 8
Page 9
…
Next page
Last page

Is there anything wrong with this page?

Help us improve

Using our website

Accessibility
Privacy
Security
Disclaimer
Copyright
Freedom of information
Acronyms and glossary terms

Quick links

Search our databases
Report a problem or side effect
TGA Business Services
Special Access Scheme
Authorised Prescriber
Office of Drug Control
State and territory contacts

Connect with us

Email subscriptions
Contact us
Facebook
(formerly Twitter)
Youtube
Instagram
LinkedIn

Help us improve

We are always looking for ways to improve our website.

Provide feedback

The Department of Health, Disability and Ageing acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.